Cargando…

Author correction to ‘Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling’ [Acta Pharmaceutica Sinica B 12 (2022) 1198–1212]

Detalles Bibliográficos
Autores principales:	Wu, Yunhao, Yu, Xiu, Wang, Yuwei, Huang, Yalin, Tang, Jiahui, Gong, Shuaishuai, Jiang, Siyu, Xia, Yuanli, Li, Fang, Yu, Boyang, Zhang, Yuanyuan, Kou, Junping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293698/ https://www.ncbi.nlm.nih.gov/pubmed/35865100 http://dx.doi.org/10.1016/j.apsb.2022.04.004

Ejemplares similares

Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling
por: Wu, Yunhao, et al.
Publicado: (2022)

The myosin II inhibitor, blebbistatin, ameliorates pulmonary endothelial barrier dysfunction in acute lung injury induced by LPS via NMMHC IIA/Wnt5a/β-catenin pathway
por: Zhang, Jiazhi, et al.
Publicado: (2022)

Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023)

NMMHC IIA triggers neuronal autophagic cell death by promoting F-actin-dependent ATG9A trafficking in cerebral ischemia/reperfusion
por: Wang, Guangyun, et al.
Publicado: (2020)

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]
por: Wu, Canhao, et al.
Publicado: (2023)

Author correction to ‘Up-regulation of glycolipid transfer protein by bicyclol causes spontaneous restriction of hepatitis C virus replication’ [Acta Pharmaceutica Sinica B 9 (2019) 769–781]
por: Huang, Meng-Hao, et al.
Publicado: (2020)

Erratum to “Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe” [Acta Pharmaceutica Sinica B 13 (2023) 2056–2070]
por: Zhang, Hongjuan, et al.
Publicado: (2023)

Ruscogenin Alleviates Myocardial Ischemia-Induced Ferroptosis through the Activation of BCAT1/BCAT2
por: Fu, Fei, et al.
Publicado: (2022)

Author correction to ‘Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome’ [Acta Pharmaceutica Sinica B 9 (2019) 734–744]
por: Wang, Zhilei, et al.
Publicado: (2020)

Author correction to ‘Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents’ [Acta Pharmaceutica Sinica B 9 (2019) 335–350]
por: Wang, Jiabing, et al.
Publicado: (2022)

Author correction to “A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease” [Acta Pharmaceutica Sinica B 12, (2021) 4032–4044]
por: Lei, Ting, et al.
Publicado: (2022)

NMMHC IIA Inhibition Ameliorates Cerebral Ischemic/Reperfusion-Induced Neuronal Apoptosis Through Caspase-3/ROCK1/MLC Pathway
por: Wang, Guang-Yun, et al.
Publicado: (2020)

Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]
por: Mei, Dong, et al.
Publicado: (2020)

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]
por: Wang, Shuyi, et al.
Publicado: (2023)

Author correction to ‘TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner’ [Acta Pharmaceutica Sinica B 11 (2021) 3994–4007]
por: Zheng, Huaqing, et al.
Publicado: (2023)

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
por: Lai, Fangfang, et al.
Publicado: (2023)

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B 12 (2022) 3934–3951]
por: Yang, Xuan, et al.
Publicado: (2023)

Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
por: Deng, Linglong, et al.
Publicado: (2023)

Author correction to “DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis” [Acta Pharmaceutica Sinica B 12 (2022) 262–273]
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Ruscogenin Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Dysfunction by Suppressing TXNIP/NLRP3 Inflammasome Activation and the MAPK Pathway
por: Cao, Guosheng, et al.
Publicado: (2016)

Remarks from Editor-in-Chief on the celebration of the 65th anniversary of Acta Biochimica et Biophysica Sinica
por: Ding, Jianping
Publicado: (2023)

Scientia Pharmaceutica, Autorenhinweise 2013
Publicado: (2013)

Scientia Pharmaceutica, Autorenhinweise 2015
Publicado: (2015)

Scientia Pharmaceutica, Autorenhinweise 2016
Publicado: (2016)

Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice’ [Acta Pharmaceutica Sinica B 13 (2023) 1164–1179]
por: Fan, Xiaoqing, et al.
Publicado: (2023)

Ruscogenin induces ferroptosis in pancreatic cancer cells
por: Song, Zhiwang, et al.
Publicado: (2020)

Acknowledgement to Reviewers of Scientia Pharmaceutica in 2017
Publicado: (2018)

A Novel Fluoroimmunoassay for Detecting Ruscogenin with Monoclonal Antibodies Conjugated with CdSe/ZnS Quantum Dots
por: Zhang, Hongwei, et al.
Publicado: (2017)

1212. Environmental Contamination Characterization of Two Outpatient Clinics
por: Warren, Bobby G, et al.
Publicado: (2019)

The Successful Relaunch of Scientia Pharmaceutica Continues Achieving Success
por: Kubelka, Wolfgang, et al.
Publicado: (2011)

DT-13 Ameliorates TNF-α-Induced Vascular Endothelial Hyperpermeability via Non-Muscle Myosin IIA and the Src/PI3K/Akt Signaling Pathway
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Ruscogenin Ameliorated Sjögren's Syndrome by Inhibiting NLRP3 Inflammasome Activation
por: He, Jing, et al.
Publicado: (2022)

Temporomandibular Disorders and Headache: A Retrospective Analysis of 1198 Patients
por: Di Paolo, Carlo, et al.
Publicado: (2017)

1212 Coccidioides Exposures and Coccidioidomycosis among Prison Employees in California
por: De Perio, Marie, et al.
Publicado: (2014)

1212. COVID-19 and the Importance of Institutional Trust to Public Health
por: Kricorian, Karin, et al.
Publicado: (2021)

Ruscogenin Ameliorates Experimental Nonalcoholic Steatohepatitis via Suppressing Lipogenesis and Inflammatory Pathway
por: Lu, Hung-Jen, et al.
Publicado: (2014)

Statistical and network analysis of 1212 COVID-19 patients in Henan, China
por: Wang, Pei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h29ebbabj470uumhrt251api30